BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aboulafia DM, Johnston R. Simvastatin-Induced Rhabdomyolysis in an HIV-Infected Patient with Coronary Artery Disease. AIDS Patient Care and STDs 2000;14:13-8. [DOI: 10.1089/108729100318091] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Dubé MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab 2011;25:429-42. [PMID: 21663837 DOI: 10.1016/j.beem.2011.04.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
2 Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. The Lancet Infectious Diseases 2007;7:787-96. [DOI: 10.1016/s1473-3099(07)70287-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
3 Smolders EJ, Ter Horst PJG, Wolters S, Burger DM. Cardiovascular Risk Management and Hepatitis C: Combining Drugs. Clin Pharmacokinet 2019;58:565-92. [PMID: 30259390 DOI: 10.1007/s40262-018-0710-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
4 Berns JS, Kasbekar N. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 2006;1:117-29. [PMID: 17699198 DOI: 10.2215/CJN.00370705] [Cited by in Crossref: 41] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
5 Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008;47:570-8. [PMID: 18176327 DOI: 10.1097/QAI.0b013e318160a542] [Cited by in Crossref: 106] [Cited by in F6Publishing: 43] [Article Influence: 7.6] [Reference Citation Analysis]
6 Cohen SD, Chawla LS, Kimmel PL. Acute kidney injury in patients with human immunodeficiency virus infection. Curr Opin Crit Care 2008;14:647-53. [PMID: 19005305 DOI: 10.1097/MCC.0b013e3283186f43] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
7 White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 2001;77:158-173. [PMID: 11402222 DOI: 10.1136/sti.77.3.158] [Cited by in Crossref: 133] [Cited by in F6Publishing: 121] [Article Influence: 6.3] [Reference Citation Analysis]
8 Lee C, Hung Y, Hsu Y, Pan T. Monascin and Ankaflavin Have More Anti-atherosclerosis Effect and Less Side Effect Involving Increasing Creatinine Phosphokinase Activity than Monacolin K under the Same Dosages. J Agric Food Chem 2013;61:143-50. [DOI: 10.1021/jf304346r] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
9 Gutierrez MDM, Mateo MG, Corbacho N, Vidal F, Domingo P. Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opin Drug Metab Toxicol 2019;15:787-802. [PMID: 31512529 DOI: 10.1080/17425255.2019.1667334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Burger D, Stroes E, Reiss P. Drug interactions between statins and antiretroviral agents: . Current Opinion in HIV and AIDS 2008;3:247-51. [DOI: 10.1097/coh.0b013e3282fbaa54] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin: . Clinical Pharmacokinetics 2008;47:463-74. [DOI: 10.2165/00003088-200847070-00003] [Cited by in Crossref: 135] [Cited by in F6Publishing: 114] [Article Influence: 9.6] [Reference Citation Analysis]
12 Barakat MG, Arora RR. Coronary Artery Disease in the Human Immunodeficiency Virus Seropositive Population. American Journal of Therapeutics 2016;23:e224-31. [DOI: 10.1097/mjt.0b013e3182973924] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Rahman AP, Eaton SA, Nguyen ST, Bain AM, Payne KD, Bedimo R, Busti AJ. Safety and Efficacy of Simvastatin for the Treatment of Dyslipidemia in Human Immunodeficiency Virus–Infected Patients Receiving Efavirenz-Based Highly Active Antiretroviral Therapy. Pharmacotherapy 2008;28:913-9. [DOI: 10.1592/phco.28.7.913] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
14 Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 2005;32:247-60. [PMID: 15902690 DOI: 10.1002/mus.20338] [Cited by in Crossref: 68] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
15 Harrison TB, Smith B. Neuromuscular manifestations of HIV/AIDS. J Clin Neuromuscul Dis 2011;13:68-84. [PMID: 22361691 DOI: 10.1097/CND.0b013e318221256f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
16 Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627. [PMID: 12942391 DOI: 10.1086/378131] [Cited by in Crossref: 429] [Cited by in F6Publishing: 368] [Article Influence: 22.6] [Reference Citation Analysis]
17 Chanson N, Bossi P, Schneider L, Bourry E, Izzedine H. Rhabdomyolysis after ezetimibe/simvastatin therapy in an HIV-infected patient. NDT Plus 2008;1:157-61. [PMID: 25983864 DOI: 10.1093/ndtplus/sfn012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Moro H, Tsukada H, Tanuma A, Shirasaki A, Iino N, Nishibori T, Nishi S, Gejyo F. Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. AIDS Patient Care STDS. 2004;18:687-690. [PMID: 15659879 DOI: 10.1089/apc.2004.18.687] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
19 Authier F, Gherardi R. Complications musculaires de l’infection par le virus de l’immunodéficience humaine (VIH) à l’ère des trithérapies. Revue Neurologique 2006;162:71-81. [DOI: 10.1016/s0035-3787(06)74984-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
20 Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am 2009;38:207-22. [PMID: 19217520 DOI: 10.1016/j.ecl.2008.11.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
21 Dau B, Holodniy M. The Relationship Between HIV Infection and Cardiovascular Disease. Curr Cardiol Rev 2008;4:203-18. [PMID: 19936197 DOI: 10.2174/157340308785160589] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
22 Malvestutto CD, Aberg JA. Management of dyslipidemia in HIV-infected patients. Clin Lipidol 2011;6:447-62. [PMID: 22216062 DOI: 10.2217/clp.11.25] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]